Model-informed COVID-19 vaccine prioritization strategies by age and serostatus
Open accessPublished version of a preprint
The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Limited initial supply of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine raises the question of how to prioritize available doses. We used a mathematical model to compare five age-stratified prioritization strategies. A highly effective transmission-blocking vaccine prioritized to adults ages 20 to 49 years minimized cumulative incidence, but mortality and years of life lost were minimized in most scenarios when the vaccine was prioritized to adults greater than 60 years old. Use of individual-level serological tests to redirect doses to seronegative individuals improved the marginal impact of each dose while potentially reducing existing inequities in COVID-19 impact. Although maximum impact prioritization strategies were broadly consistent across countries, transmission rates, vaccination rollout speeds, and estimates of naturally acquired immunity, this framework can be used to compare impacts of prioritization strategies across contexts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Impacts of vaccine prioritization strategies on mortality and infections. (A) Distribution of vaccines for five prioritization strategies: under 20 years, adults 20 to 49 years, adults 20+ years, adults 60+ years, and all ages. (B, C, F, and G) Example simulation curves show [(B) and (C)] percentage of the total population infected over time and [(F) and (G)] cumulative mortality for no vaccines (gray dashed lines) and for five different prioritization strategies [colored lines matching (A)], with [(B) and (F)] 10% and [(C) and (G)] 30% vaccine supply. (D, E, H, and I) Summary curves show percent reductions in [(D) and (E)] infections and [(H) and (I)] deaths in comparison to an unmitigated outbreak for vaccine supplies between 1 and 50% after 365 days of simulation. Squares and diamonds show how the outputs from single simulations [(F) and (G)] correspond to points in summary curves (H). Gray shading indicates the period during which vaccine is being rolled out at 0.2% of total population per day. Black dots indicate break points at which prioritized demographic groups have been 70% vaccinated, after which vaccines are distributed without prioritization. These simulations assume contact patterns and demographics of the United States (38, 53) and an all-or-nothing, transmission-blocking vaccine with 90% vaccine efficacy and R0 = 1.5 (scenario 2) and R0 = 1.15 (scenario 1).](https://figures.cochat.ai/paper-figures/040af1c419fe4105805e757ba6eecdfa/model-informed-covid-19-vaccine-prioritization-strategies-by-age-and-serostatus-figure-1.jpg)
![Fig. 2 Mortality-minimizing vaccine prioritization strategies across reproductive numbers R0 and countries. (A to E) Heatmaps show the prioritization strategies that result in maximum reduction of mortality for varying values of [(A) and (B)] the basic reproductive number R0 and [(C), (D), and (E)] across nine countries, for vaccine supplies between 1 and 50% of the total population, for an all-or-nothing and transmission-blocking vaccine, 90% vaccine efficacy. [(A) and (B)] Contact patterns and demographics of the United States (38, 53). [(C), (D), and (E)] Contact patterns and demographics of POL, Poland; ZAF, South Africa; CHN, China; BRA, Brazil; ZWE, Zimbabwe; ESP, Spain; IND, India; USA, United States of America; and BEL, Belgium, with R0 and rollout speeds as indicated.](https://figures.cochat.ai/paper-figures/3232e6d2c98d4491b422e996e35f7beb/model-informed-covid-19-vaccine-prioritization-strategies-by-age-and-serostatus-figure-2.jpg)
![Fig. 3 Effects of age-dependent vaccine efficacy on the impacts of prioritization strategies. (A) Diagram of hypothetical age-dependent vaccine efficacy shows decrease from 90% baseline efficacy to 50% efficacy among individuals aged 80+ years, beginning at age 60 (dashed line). (B and C) Percent reduction in deaths in comparison with an unmitigated outbreak for transmission-blocking all-or-nothing vaccines with either constant 90% efficacy for all age groups (solid lines) or age-dependent efficacy shown in (A) (dashed lines), covering scenario 1 [0.2% rollout per day, R0 = 1.15; (B)] and scenario 2 [0.2% rollout per day, R0 = 1.5 (C)]. Black dots indicate break points at which prioritized demographic groups have been 70% vaccinated, after which vaccines are distributed without prioritization. Shown are contact patterns and demographics of the United States (38, 53); all-or-nothing and transmission-blocking vaccine.](https://figures.cochat.ai/paper-figures/85e54e74290b4a1b82ec5b49b5f8d03f/model-informed-covid-19-vaccine-prioritization-strategies-by-age-and-serostatus-figure-3.jpg)
![Fig. 4 Effects of existing seropositivity on the impacts of prioritization strategies. (A to C) Percent reductions in (A) infections, (B) deaths, and (C) years of life lost (YLL) for prioritization strategies when existing age-stratified seroprevalence is incorporated [August 2020 estimates for New York City; mean seroprevalence 26.9% (28)]. Plots show reductions for scenario 2 (0.2% rollout per day, R0 = 1.5) when vaccines are given to all individuals (solid lines) or to only seronegatives (dashed lines), inclusive of 96% serotest sensitivity, 99% specificity (54), and approximately 3 months of seroreversion (supplementary materials, materials and methods) (29). Shown are U.S. contact patterns and demographics (38, 53), all-or-nothing and transmission-blocking vaccine with 90% vaccine efficacy. Lower and higher seroprevalence examples are provided in figs. S12 and S13, respectively.](https://figures.cochat.ai/paper-figures/4122f4138dc44271af1ce6fd7d40abb0/model-informed-covid-19-vaccine-prioritization-strategies-by-age-and-serostatus-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Vaccination alone is not expected to be able to control the spread of the infection, and a carefully planned vaccination campaign25,26 needs to be coordinated with continued implementation of NPIs27 until sufficient coverage is reached to make the case fatality rate (CFR) similar to that of seasonal influenza.”
From Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy (2021) · cites this paper as [25]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.
Dan, J. M., Mateus, J., Kato, Y., Hastie, K. M., Yu, E. D., Faliti, C. E., Grifoni, A., Ramirez, S. I., Haupt, S., Frazier, A., et al. (2021) · Science · doi:10.1126/science.abf4063 · Cited by 2,656
COVID-19 and Racial/Ethnic Disparities
Webb Hooper, M., Nápoles, A. M., & Pérez-Stable, E. J. (2020) · JAMA · doi:10.1001/jama.2020.8598 · Cited by 2,047 · cited 1×
“However, other factors correlate with disease outcomes, such as treatment and healthcare access and comorbidities, which may correlate with factors like rural vs urban location, socioeconomic status, sex ( 41, 42 ), and race and ethnicity ( 43 ), that are not accounted for in this study.”
Age-dependent effects in the transmission and control of COVID-19 epidemics
Davies, N. G., Klepac, P., Liu, Y., Prem, K., Jit, M., CMMID COVID-19 working group, Pearson, C. A. B., Quilty, B. J., Kucharski, A. J., Gibbs, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0962-9 · Cited by 1,759 · cited 1×
“Age-stratified susceptibility values were drawn from literature estimates ( 13 ).”
Sex differences in immune responses that underlie COVID-19 disease outcomes
Takahashi, T., Ellingson, M. K., Wong, P., Israelow, B., Lucas, C., Klein, J., Silva, J., Mao, T., Oh, J. E., Tokuyama, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2700-3 · Cited by 1,459 · cited 1×
“However, other factors correlate with disease outcomes, such as treatment and healthcare access and comorbidities, which may correlate with factors like rural vs urban location, socioeconomic status, sex ( 41, 42 ), and race and ethnicity ( 43 ), that are not accounted for in this study.”
Why does COVID-19 disproportionately affect older people?
Mueller, A. L., McNamara, M. S., & Sinclair, D. A. (2020) · Aging · doi:10.18632/aging.103344 · Cited by 1,128 · cited 1×
“We evaluated the impact of vaccine prioritization strategies using an age-stratified SEIR model, because age has been shown to be an important correlate of susceptibility ( 12–14 ), seroprevalence ( 12,15 ), severity ( 16–18 ), and mortality ( 19,20 ).”
Changes in contact patterns shape the dynamics of the COVID-19 outbreak in China
Zhang, J., Litvinova, M., Liang, Y., Wang, Y., Wang, W., Zhao, S., Wu, Q., Merler, S., Viboud, C., Vespignani, A., et al. (2020) · Science · doi:10.1126/science.abb8001 · Cited by 1,107 · cited 1×
“We evaluated the impact of vaccine prioritization strategies using an age-stratified SEIR model, because age has been shown to be an important correlate of susceptibility ( 12–14 ), seroprevalence ( 12,15 ), severity ( 16–18 ), and mortality ( 19,20 ).”
The Efficacy of Influenza Vaccine in Elderly Persons: A Meta-Analysis and Review of the Literature
Gross, P. A., Hermogenes, A. W., Sacks, H. S., Lau, J., & Levandowski, R. A. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-7-199510010-00008 · Cited by 1,100 · cited 1×
“COVID-19 vaccines may not be equally effective across age groups in preventing infection or transmission, a phenomenon known to affect influenza vaccines ( 23–26 ).”
Estimating the burden of SARS-CoV-2 in France
Salje, H., Tran Kiem, C., Lefrancq, N., Courtejoie, N., Bosetti, P., Paireau, J., Andronico, A., Hozé, N., Richet, J., Dubost, C.-L., et al. (2020) · Science · doi:10.1126/science.abc3517 · Cited by 1,038
Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers
Lumley, S. F., O’Donnell, D., Stoesser, N. E., Matthews, P. C., Howarth, A., Hatch, S. B., Marsden, B. D., Cox, S., James, T., Warren, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2034545 · Cited by 940 · cited 2×
“Serostatus itself is an imperfect indicator of protection, and the relationship of prior infection, serostatus, and protection may change over time (10, 29,32,33).”
Govaert, T. M. E. (1994) · JAMA · doi:10.1001/jama.1994.03520210045030 · Cited by 867
Research works printed but not linked: 1
- K. E. Atkinson An Introduction to Numerical Analysis (Wiley 1989) chap. 2 pp. 56–58 second edn.
Cited by
Items 201–300 of 777
The impact of age structure and vaccine prioritization on COVID-19 in West Africa
Taboe, H. B., Asare-Baah, M., Yesmin, A., & Ngonghala, C. N. (2022) · Infectious Disease Modelling · doi:10.1016/j.idm.2022.08.006 · Cited by 22
Rodríguez, J., Patón, M., & Acuna, J. M. (2020) · medRxiv · doi:10.1101/2020.10.12.20211094 · Cited by 19
Auton, J. C., & Sturman, D. (2022) · Health Promotion International · doi:10.1093/heapro/daac089 · Cited by 17
“Since December 2019, the coronavirus disease 2019 (COVID-19) has been an international public health emergency (Bubar et al., 2021; Chang et al., 2020).”
BackgroundFerreira, L. S., de Almeida, G. B., Borges, M. E., Simon, L. M., Poloni, S., Bagattini, Â. M., da Rosa, M. Q. M., Diniz‐Filho, J. A. F., Kuchenbecker, R. D. S., Camey, S. A., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.09.082 · Cited by 19
“(31) when considering the number 10 of deaths as the outcome.”
BackgroundCooperating Graph Neural Networks With Deep Reinforcement Learning for Vaccine Prioritization
Ling, L., Mondal, W. U., & Ukkusuri, S. V. (2024) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2024.3392436 · Cited by 17
“However, they strongly rely on homogeneity assumption in the subgroup of the population such as age [5, 19, 45] and occupancy [22, 23, 41].”
BackgroundRachaniotis, N. P., Dasaklis, T. K., Fotopoulos, F., & Tinios, P. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18052497 · Cited by 18
Ayalon, L., Peisah, C., Lima, C. D. M., Verbeek, H., & Rabheru, K. (2021) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2021.06.017 · Cited by 17
Gianfagna, F., Veronesi, G., Baj, A., Gasperina, D. D., Siclari, S., Ferrante, F. D., Maggi, F., Iacoviello, L., & Ferrario, M. (2022) · Scientific Reports · doi:10.1038/s41598-021-04344-y · Cited by 17
Salo, H., Lehtonen, T., Auranen, K. J., Baum, U., & Leino, T. M. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.04.055 · Cited by 18
“[15] For example, one of the questions was 51 whether the elderly or individuals with certain background illnesses should be prioritised for 52 COVID-19 vaccination.[15] Along with the other European Union countries, Finland joined a 53 common procurement system and subsequently commenced COVID-19 vaccinations in late…”
BackgroundKo, Y., Mendoza, V. M. P., Mendoza, R., Seo, Y. B., Lee, J., Lee, J., Kwon, D., & Jung, E. (2022) · Journal of Korean Medical Science · doi:10.3346/jkms.2022.37.e209 · Cited by 17
Gendy, M. E. G., & Yuce, M. R. (2022) · IEEE Reviews in Biomedical Engineering · doi:10.1109/rbme.2022.3219433 · Cited by 20
“ML and AI can participate in the process of vaccine management and surveillance, [135] built an ML model that monitors different drive-through mass vaccination facilities, whereas [136] compares age and serostatus-stratified priority in ML algorithms.”
BackgroundCovidXAI : explainable AI assisted web application for COVID ‐19 vaccine prioritization
Chowdhury, D., Poddar, S., Banarjee, S., Pal, R., Gani, A., Ellis, C., Arya, R. C., Gill, S. S., & Uhlig, S. (2022) · Internet Technology Letters · doi:10.1002/itl2.381 · Cited by 16
Modelling multiscale infectious disease in complex systems
Xian, J., Liu, M., Cheng, X., Yang, M., Xie, T., Wang, X., Liu, M., Zhang, Y., Yang, D., Sun, G., et al. (2025) · Physics Reports · doi:10.1016/j.physrep.2025.01.006 · Cited by 16
Routledge, I., Epstein, A., Takahashi, S., Janson, O., Hakim, J. M. C., Duarte, E. M., Turcios, K., Vinden, J., Sujishi, K. K., Rangel, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23651-6 · Cited by 16
Designing the Safe Reopening of US Towns Through High‐Resolution Agent‐Based Modeling
Truszkowska, A., Thakore, M., Zino, L., Butail, S., Caroppo, E., Jiang, Z., Rizzo, A., & Porfiri, M. (2021) · Advanced Theory and Simulations · doi:10.1002/adts.202100157 · Cited by 16
Truszkowska, A., Zino, L., Butail, S., Caroppo, E., Jiang, Z., Rizzo, A., & Porfiri, M. (2022) · Advanced Theory and Simulations · doi:10.1002/adts.202100521 · Cited by 16
Jiménez-Rodríguez, P., Muñoz-Fernández, G. A., Rodrigo-Chocano, J. C., Seoane-Sepúlveda, J. B., & Weber, A. (2021) · Journal of Mathematical Analysis and Applications · doi:10.1016/j.jmaa.2021.125975 · Cited by 16
Anatomy of the first six months of COVID-19 vaccination campaign in Italy
Gozzi, N., Chinazzi, M., Davis, J. T., Mu, K., y Piontti, A. P., Ajelli, M., Perra, N., & Vespignani, A. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1010146 · Cited by 16
Tang, B., Zhang, X., Li, Q., Bragazzi, N. L., Golemi, D., & Wu, J. (2022) · BMC Public Health · doi:10.1186/s12889-022-13429-w · Cited by 16
Damasceno, D. H. P., Amaral, A. A., Silva, C. A., & Silva, A. C. S. E. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210902094254 · Cited by 17
Modeling the transmission mitigation impact of testing for infectious diseases
Middleton, C. E., & Larremore, D. B. (2024) · Science Advances · doi:10.1126/sciadv.adk5108 · Cited by 15
“Third, this work adds TE to the set of estimates quantifying the effectiveness of targeted interventions that can be directly incorporated as single parameters in between-host transmission models, including VE ( 55 ) and preexposure prophylaxis efficacy ( 56 ).”
Self-citationModelling infectious diseases with herd immunity in a randomly mixed population
Law, K. B., Peariasamy, K. M., Ibrahim, H. M., & Abdullah, N. H. (2021) · Scientific Reports · doi:10.1038/s41598-021-00013-2 · Cited by 15
A Modeling Study on Vaccination and Spread of SARS-CoV-2 Variants in Italy
Antonini, C., Calandrini, S., & Bianconi, F. (2021) · Vaccines · doi:10.3390/vaccines9080915 · Cited by 15
“Given this scenario, epidemiological models play a crucial role in exploring the future trajectory of COVID-19 and assessing the role of immunity response and the impact of new variants [16,17].”
BackgroundReopening California: Seeking robust, non-dominated COVID-19 exit strategies
de Lima, P. N., Lempert, R. J., Vardavas, R., Baker, L., Ringel, J., Rutter, C. M., Ozik, J., & Collier, N. T. (2021) · PLoS ONE · doi:10.1371/journal.pone.0259166 · Cited by 17
Modeling strategies for the allocation of SARS-CoV-2 vaccines in the United States
Walker, J., Paul, P., Dooling, K. L., Oliver, S. E., Prasad, P. V., Steele, M. K., Gastañaduy, P. A., Johansson, M. A., Biggerstaff, M., & Slayton, R. B. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.02.015 · Cited by 16
“[15] Meanwhile, results in this analysis were robust to the prevalence of acute infection at the time of vaccination.”
Projecting vaccine demand and impact for emerging zoonotic pathogens
Lerch, A., ten Bosch, Q. A., Jackson, M. L., Bettis, A. A., Bernuzzi, M., Murphy, G. A. V., Tran, Q. M., Huber, J. H., Siraj, A. S., Bron, G. M., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02405-1 · Cited by 15
Optimal vaccination strategies using a distributed model applied to COVID-19
Angelov, G., Kovacevic, R. M., Stilianakis, N. I., & Veliov, V. M. (2022) · Central European Journal of Operations Research · doi:10.1007/s10100-022-00819-z · Cited by 15
“The economic consequences of “lock-down” have been recently investigated in several papers, e.g. (Acemoglu et al. 2000; Bloom et al. 2000; Kovacevic et al. 2022; Caulkins et al. 2021).”
BackgroundA data-driven spatially-specific vaccine allocation framework for COVID-19
Hong, Z., Li, Y., Gong, Y. Y., & Chen, W. (2022) · Annals of Operations Research · doi:10.1007/s10479-022-05037-z · Cited by 16
“Accordingtotheliterature,mostCOVID-19vaccineallocationpoliciesarebasedonage (Bubaretal.,2021;Matrajtetal.,2020).”
Luebben, G., González‐Parra, G., & Cervantes, B. (2023) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2023481 · Cited by 15
“Another interesting result that was found for influenza vaccination is that direct protection (efficacy against the disease) is superior when reproduction numbers are high but indirect protection (transmission of the virus) is superior when transmission is low [3, 20].”
BackgroundMethodNo Panic in Pandemic: The Impact of Individual Choice on Public Health Policy
Bai, M., Cui, Y., Kong, G., & Zhang, A. Z. (2021) · Manufacturing & Service Operations Management · doi:10.1287/msom.2022.0514 · Cited by 15
An Adaptive Research Approach to COVID-19 Forecasting for Regional Health Systems in England
Betcheva, L., Erhun, F., Feylessoufi, A., Fryers, P., Gonçalves, P., Jiang, H., Kattuman, P. A., Pape, T., Pari, A. A. A., Scholtes, S., et al. (2024) · INFORMS Journal on Applied Analytics · doi:10.1287/inte.2023.0009 · Cited by 17
González‐Parra, G., Mahmud, M. S., & Kadelka, C. (2024) · Infectious Disease Modelling · doi:10.1016/j.idm.2024.05.005 · Cited by 16
“One prominent study agrees that younger individuals should only be prioritized, when minimizing deaths, if effective reproductive numbers are low but fi nds that a slow roll-out (and not a fast one) is an additional requirement (Bubar et al., 2021).”
BackgroundMethodInfluentialVaccination strategies for a seasonal epidemic: a simple SIR model
Nakamura, G. M., Grammaticos, B., & Badoual, M. (2021) · Open Communications in Nonlinear Mathematical Physics · doi:10.46298/ocnmp.7463 · Cited by 15
“Bubar et al [46] addressed the question of prioritisation in the light of a relatively limited initial supply of vaccines.”
Hartnett, G. S., Parker, E., Gulden, T. R., Vardavas, R., & Kravitz, D. W. (2021) · Journal of Complex Networks · doi:10.1093/comnet/cnab042 · Cited by 22
Rosenstrom, E., Mele, J., Ivy, J. S., Mayorga, M. E., Patel, M. D., Lich, K. H., Johnson, K., Delamater, P. L., Keskinocak, P., Boyce, R. M., et al. (2022) · PNAS Nexus · doi:10.1093/pnasnexus/pgab004 · Cited by 15
Vacinas contra a Covid-19: a doença e as vacinas como armas na opressão colonial
Filho, H. R. C., & Ribeiro, A. A. (2021) · Saúde em Debate · doi:10.1590/0103-1104202112800 · Cited by 15
Velasco, M., Galán, M. A., Casas, M. L. M. D. L., Pérez‐Fernández, E., Martínez-Ponce, D., González-Piñeiro, B., Castilla, V., Guijarro, C., Alcorcón COVID-19 Working Group, Weber, A. A., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab299 · Cited by 15
“As no trial has evaluated the mediumterm protective effects of a single-dose mRNA protocol, health policy makers rely on surrogate markers, such as SARS-CoV-2 seropositivity prior to vaccination, for this difficult decision [12].”
Violán, C., Carrasco-Ribelles, L., Collatuzzo, G., Ditano, G., Abedini, M., Janke, C., Reinkemeyer, C., Giang, L. T. T., Liviero, F., Scapellato, M. L., et al. (2023) · Vaccines · doi:10.3390/vaccines11081340 · Cited by 14
Early mathematical models of COVID-19 vaccination in high-income countries: a systematic review
Burch, E., Khan, S. A., Stone, J., Asgharzadeh, A., Dawe, J., Ward, Z., Brooks‐Pollock, E., & Christensen, H. (2024) · Public Health · doi:10.1016/j.puhe.2024.07.029 · Cited by 15
Vaccine failure mode determines population-level impact of vaccination campaigns during epidemics
Lee, D., Nande, A., Anderson, T. L., Levy, M. Z., & Hill, A. L. (2025) · Journal of The Royal Society Interface · doi:10.1098/rsif.2024.0689 · Cited by 15
“Very few considered how the choice of modeling vaccine failure might affect conclusions (for some exceptions, see [25–28]).”
Thompson, K. M., Kalkowska, D. A., & Badizadegan, K. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1891889 · Cited by 14
Bosbach, W. A., Heinrich, M., Kolisch, R., & Heiß, C. (2021) · Vaccines · doi:10.3390/vaccines9060546 · Cited by 14
“A similar project with results for an entire population, split by age groups, is published in [18], and pre-Corona work about hospital staff in [3,4,7].”
ResultHarman, J. L., Weinhardt, J. M., Beck, J. W., & Mai, I. (2021) · Scientific Reports · doi:10.1038/s41598-021-95134-z · Cited by 16
Rahman, A., Kuddus, M. A., Ip, R. H. L., & Bewong, M. (2021) · Viruses · doi:10.3390/v13112185 · Cited by 16
“Vaccination is often considered the best way to prevent or control outbreaks of infectious diseases including COVID-19 [64].”
BackgroundHoang, V. T., Pham, D. T., Nguyen, Q. T., Nguyen, D. C., Nguyen, D. T., Nguyen, T. B., Tran, T. K. T., Phan, T. L., Vo, P. L. N., Dao, T. L., et al. (2022) · Tropical Medicine & International Health · doi:10.1111/tmi.13744 · Cited by 14
“The proportion of the infected population or recovered from COVID19 would be an important measure to inform policies at community level, including when and how social distancing can be eased, and prioritising vaccines [19].”
BackgroundYong, B., Hoseana, J., & Owen, L. (2022) · Infectious Disease Modelling · doi:10.1016/j.idm.2022.06.004 · Cited by 14
“…et al., 2021; Sadarangani et al., 2021), starting vaccinations as early as possible (Albani, Loria, Massad, & Zubelli, 2021a, 2021b; Amaku et al., 2021a), and devising vaccination strategies such as age-based prioritisations (Bubar et al., 2021; LimaCampos, Cysne, Madureira, & Mendes, 2021).”
COVID-19 vaccination challenges: A mini-review
Afshar, Z. M., Barary, M., Hosseinzadeh, R., Karim, B., Ebrahimpour, S., Nazary, K., Sio, T. T. W., Sullman, M. J. M., Carson‐Chahhoud, K., Moudi, E., et al. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2066425 · Cited by 15
“protective and even those with a history of prior SARS-CoV-2 infection are vulnerable to reinfections, meaning that these individuals should not be excluded from the vaccination program.(105)”
BackgroundMeasuring the impact of COVID-19 vaccination and immunity waning: A modelling study for Portugal
Caetano, C., Morgado, M. L., Patrício, P., Leite, A., Machado, A., Torres, A., Pereira, J. F., Namorado, S., Sottomayor, A., Peralta‐Santos, A., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.10.007 · Cited by 15
“While such programmes are promising, several modelling studies have shown that as vaccination is rolled out, proper vaccine allocation is necessary [5, 6, 7, 8, 9] and maintenance of NPIs is still required to prevent the increase of hospitalisations and deaths, particularly before completing full vaccination [10, 11,…”
BackgroundQuantifying the impact of SARS-CoV-2 temporal vaccination trends and disparities on disease control
Larsen, S. L., Shin, I., Joseph, J., West, H., Anorga, R., Mena, G. E., Mahmud, A. S., & Martinez, P. P. (2023) · Science Advances · doi:10.1126/sciadv.adh9920 · Cited by 17
“Mathematical models have been useful in understanding optimal SARS-CoV-2 vaccine prioritization strategies based on age ( 16 ) and vaccine sharing to places with lower vaccine availability ( 17 , 18 ).”
Developing a national pandemic vaccination calendar under supply uncertainty
Karakaya, S., & Balcik, B. (2023) · Omega · doi:10.1016/j.omega.2023.103001 · Cited by 14
The systemic pro-inflammatory response: targeting the dangerous liaison between COVID-19 and cancer
Dettorre, G. M., Patel, M., Gennari, A., Pentheroudakis, G. E., Romano, E., Cortellini, A., & Pinato, D. J. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100123 · Cited by 14
Ethical reflections on Covid-19 vaccines
Raus, K., Mortier, E. P., & Eeckloo, K. (2021) · Acta Clinica Belgica · doi:10.1080/17843286.2021.1925027 · Cited by 14
“A recent modelling study, for example, used various simulations to determine which vaccination prioritization is best at minimizing mortality [17].”
MethodRumpler, É., Feldman, J. M., Bassett, M. T., & Lipsitch, M. (2023) · PLOS Global Public Health · doi:10.1371/journal.pgph.0001378 · Cited by 14
“As it has been show that vaccination strategies targeting younger adults can lead to lower number of infections but higher number of deaths [9], it is possible that vaccinating front-line workers would lead to fewer infections.”
BackgroundSelf-citationPettoello‐Mantovani, M., Carrasco-Sanz, A., Huss, G., Meštrović, J., Vural, M., Pop, T. L., Ferrara, P., Somekh, E., Mujkić, A., Hoey, H., et al. (2021) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2021.09.013 · Cited by 14
“Two main approaches may be considered in vaccine prioritization: directly vaccinate people at greatest risk for severe outcomes and indirectly protect the weakest part of the population by vaccinating those who do the most transmitting.(12) The experience provided by the influenza vaccination programs, which suggest t…”
BackgroundVaccination strategies in structured populations under partial immunity and reinfection
Rodríguez-Maroto, G., Atienza-Diez, I., Ares, S., & Manrubia, S. C. (2023) · Journal of Physics A Mathematical and Theoretical · doi:10.1088/1751-8121/accda3 · Cited by 13
“…other model-based studies showing that the optimal vaccination strategy balancing direct and indirect protection against COVID-19 is highly determined by vaccine supply and efficacy [14,45,46] and vaccination of the most susceptible group is more efficient under a broad range of situations [47,48].”
BackgroundMethodInfluentialAli, S., Li, Z., Moqueet, N., Moghadas, S. M., Galvani, A. P., Cooper, L. A., Stranges, S., Haworth-Brockman, M. J., Pinto, A. D., Asaria, M., et al. (2024) · Medical Decision Making · doi:10.1177/0272989x241280611 · Cited by 13
Sprengholz, P., Korn, L., Eitze, S., & Betsch, C. (2021) · Journal of Medical Ethics · doi:10.1136/medethics-2021-107339 · Cited by 15
Zhang, L., Wu, L., Xu, X., Yuan, Y., Jiang, R., Yan, X., Zhang, X., Gao, Y., Shang, H., Lian, B., et al. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/8733598 · Cited by 13
“Due to the limited supply of effective vaccines [11], methods to reduce disease spread such as avoiding crowds, wearing masks, and keeping physical distance are still important strategies to fight this infection [12, 13].”
BackgroundAn iterative algorithm for optimizing COVID-19 vaccination strategies considering unknown supply
Bicher, M., Rippinger, C., Zechmeister, M., Jahn, B., Sroczynski, G., Mühlberger, N., Santamaria-Navarro, J., Urach, C., Brunmeir, D., Siebert, U., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0265957 · Cited by 13
“While some of them limit their findings on evaluating several previously fixed strategies [2], others use different optimization algorithms to find the best solution in a given parameter space [3, 4].”
BackgroundEthnic homophily affects vaccine prioritization strategies
Kadelka, C., Islam, M. R., McCombs, A., Alston, J., & Morton, N. (2022) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2022.111295 · Cited by 14
Ye, Y., Huang, L., Wang, J., Chuang, Y., & Pan, L. (2022) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-022-02074-3 · Cited by 13
Modelling the impact of the Omicron BA.5 subvariant in New Zealand
Lustig, A. G., Vattiato, G., Maclaren, O. J., Watson, L. M., Datta, S., & Plank, M. J. (2023) · Journal of The Royal Society Interface · doi:10.1098/rsif.2022.0698 · Cited by 14
Mathematical Modeling Evaluates How Vaccinations Affected the Course of COVID-19 Disease Progression
Tzamali, E., Sakkalis, V., Tzedakis, G., Spanakis, E. G., & Tzanakis, N. (2023) · Vaccines · doi:10.3390/vaccines11040722 · Cited by 13
Oh, S.-Y., & Seo, H. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e15668 · Cited by 13
COVID-19 Pandemic in India: Through the Lens of Modeling
Babu, G. R., Ray, D., Bhaduri, R., Halder, A., Kundu, R., Menon, G. I., & Mukherjee, B. (2021) · Global Health Science and Practice · doi:10.9745/ghsp-d-21-00233 · Cited by 15
“Bubar et al.53 use amathematical model accounting for vaccine efficacy and age-related variations in susceptibility, immunity, and fatality rates to prioritize available doses.”
Sachak-Patwa, R., Byrne, H. M., Dyson, L., & Thompson, R. N. (2021) · Communications Medicine · doi:10.1038/s43856-021-00038-8 · Cited by 17
Dong, Y., He, Z., Liu, T., Huang, J. V., Zhang, C. J. P., Akinwunmi, B. O., & Ming, W. (2022) · Vaccines · doi:10.3390/vaccines10060832 · Cited by 13
Lu, D. Z., Aleta, A., Ajelli, M., Pastor‐Satorras, R., Vespignani, A., & Moreno, Y. (2021) · medRxiv · doi:10.1101/2021.03.19.21253974 · Cited by 16
Anupong, S., Chantanasaro, T., Wilasang, C., Jitsuk, N. C., Sararat, C., Sornbundit, K., Pattanasiri, B., Wannigama, D. L., Amarasiri, M., Chadsuthi, S., et al. (2023) · Infectious Disease Modelling · doi:10.1016/j.idm.2023.11.003 · Cited by 12
Standing the test of COVID-19: charting the new frontiers of medicine
Cauchemez, S., Cossu, G., Delzenne, N. M., Elinav, E., Fassin, D., Fischer, A., Härtung, T., Kalra, D., Netea, M. G., Neyts, J. H., et al. (2024) · Frontiers in Science · doi:10.3389/fsci.2024.1236919 · Cited by 14
Mohammadi, M., Asgari, E., Karimi-Mamaghan, M., Pirayesh, A., & Woensel, T. V. (2024) · Omega · doi:10.1016/j.omega.2024.103133 · Cited by 12
Lin, Q., Wang, Q., Chen, B., Ye, Y., Ma, L., & Tan, K. C. (2024) · IEEE Transactions on Evolutionary Computation · doi:10.1109/tevc.2024.3467048 · Cited by 12
Gaetano, A. D., Barrat, A., & Paolotti, D. (2024) · Mathematical Biosciences · doi:10.1016/j.mbs.2024.109337 · Cited by 12
McAlister, F. A., Bushnik, T., Leung, A. A. C., & Saxinger, L. M. (2021) · Canadian Medical Association Journal · doi:10.1503/cmaj.210529 · Cited by 12
Li, R., Bjørnstad, O. N., & Stenseth, N. C. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100200 · Cited by 12
Transmission dynamics model and the coronavirus disease 2019 epidemic: applications and challenges
Guan, J., Zhao, Y. C., Wei, Y., Shen, S., You, D., Zhang, R., Lange, T., & Chen, F. (2022) · Medical Review · doi:10.1515/mr-2021-0022 · Cited by 12
“Bubar et al. developed an age-strati fi ed SEIR model accounting for age structures in different countries to evaluate and generate vaccine prioritization strategies for SARS-CoV-2 [132].”
BackgroundHotton, A., Ozik, J., Kaligotla, C., Collier, N., Stevens, A., Khanna, A. S., MacDonell, M. M., Wang, C., LePoire, D. J., Chang, Y., et al. (2022) · Annals of Epidemiology · doi:10.1016/j.annepidem.2022.06.005 · Cited by 13
Why does COVID-19 continue to spread despite mass vaccination?
Zhang, S., Yang, Z., Chen, Z.-L., Yue, S., Zhang, S., & Tang, Y. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.938108 · Cited by 12
“And vaccination priority for adults 20 to 49 years of age minimizes cumulative morbidity, but when vaccination priority is given to adults over 60 years of age, mortality and life loss are minimized in most cases (41).”
BackgroundAnderson, T. L., Nande, A., Merenstein, C., Bellotti, B. R., Oommen, A., Kelly, B. J., Levy, M. Z., & Hill, A. L. (2023) · Epidemics · doi:10.1016/j.epidem.2023.100710 · Cited by 14
León, T. M., Vargo, J., Pan, E., Jain, S., & Shete, P. B. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab415 · Cited by 12
“We used a modified, age-stratified compartmental (SusceptibleExposed-Infectious-Recovered) model based on a previously published model [7] and parameterized for the state of California.”
BackgroundMethodBeck, E. J., Hsieh, Y., Fernández, R. E., Dashler, G., Egbert, E. R., Truelove, S. A., Garliss, C. C., Wang, R., Bloch, E. M., Shrestha, R., et al. (2022) · Journal of Clinical Microbiology · doi:10.1128/jcm.02390-21 · Cited by 12
“Surprisingly, despite prioritizing older Americans during the vaccine rollout (29), patients older than 60 were as”
BackgroundSong, B., Wang, X., Sun, P., & Boukerche, A. (2023) · Journal of Network and Computer Applications · doi:10.1016/j.jnca.2023.103715 · Cited by 11
Bongiorno, C., & Zino, L. (2022) · Applied Network Science · doi:10.1007/s41109-022-00449-z · Cited by 11
“These features could be easily incorporated within our modeling framework, following implementations similar to the one proposed in the recent literature (Grauer et al. 2020; Bubar et al. 2021; Truszkowska et al. 2021; Foy et al. 2021; Parino et al. 2021).”
BackgroundMethodYasuda, H., Ito, F., Hanaki, K., & Suzuki, K. (2022) · Archives of Public Health · doi:10.1186/s13690-022-00933-z · Cited by 11
“Studies in the US have demonstrated that vaccinating the elderly population specifically, rather than vaccinating a given group with numerous infected people, was superior in terms of protecting elderly people [29, 30].”
BackgroundAkil, L., Barner, Y. M., Bisht, A., Okoye, E., & Ahmad, H. A. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph192113990 · Cited by 11
“In addition, prioritizing vaccination to older populations over 60 years of age and those with comorbidities to reduce fatalities in these populations may have impacted the spread of the virus among individuals under 50 years of age, especially in disadvantaged populations [39].”
BackgroundAge-Stratified Model to Assess Health Outcomes of COVID-19 Vaccination Strategies, Ghana
Ofori, S. K., Schwind, J. S., Sullivan, K. L., Chowell, G., Cowling, B. J., & Fung, I. C. (2023) · Emerging infectious diseases · doi:10.3201/eid2902.221098 · Cited by 11
“Bubar et al. concluded in their multicountry research that the cumulative incidence of COVID-19 was lowest when adults 20–49 years of age were prioritized, especially with a highly effective transmis-sion-blocking vaccine ( 13 ).”
InfluentialThe benefits and costs of U.S. employer COVID‐19 vaccine mandates
Ferranna, M., Robinson, L. A., Cadarette, D., Eber, M. R., & Bloom, D. E. (2023) · Risk Analysis · doi:10.1111/risa.14090 · Cited by 11
Priority age targets for COVID-19 vaccination in Ethiopia under limited vaccine supply
Galli, M., Zardini, A., Gamshie, W. N., Santini, S., Tsegaye, A., Trentini, F., Marziano, V., Guzzetta, G., Manica, M., d’Andrea, V., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-32501-y · Cited by 11
“Our findings therefore confirm the results obtained across different countries in early 2021 [28,39,40].”
ResultExamining the Influence of Imbalanced Social Contact Matrices in Epidemic Models
Hamilton, M. A., Knight, J., & Mishra, S. (2023) · American Journal of Epidemiology · doi:10.1093/aje/kwad185 · Cited by 11
“Numerous mathematical transmission models have used contact data from POLYMOD and Prem et al., but many lack description of methods applied to handle the imbalanced (i.e., nonreciprocal) nature of these matrices (6, 14– 16).”
BackgroundMethodItalia, M., Rossa, F. D., & Dercole, F. (2023) · Scientific Reports · doi:10.1038/s41598-023-48465-y · Cited by 11
“Vaccine protection could also be made age-dependent 26 and discriminate between effectiveness against infection and severe outcomes 64–67 .”
Ma, B., Qi, J., Wu, Y., Wang, P., Li, D., & Liu, S. (2022) · Digital Signal Processing · doi:10.1016/j.dsp.2022.103577 · Cited by 11
“Except for the high transmission rate, the epidemic has caused enormous social and economic damage [8–11].”
Fosdick, B. K., Bayham, J., Dilliott, J., Ebel, G. D., & Ehrhart, N. P. (2022) · Infectious Disease Modelling · doi:10.1016/j.idm.2022.07.003 · Cited by 11
“We assume a vaccine ef fi cacy of 95% in an “ all-or-nothing ” framework, such that 5% of those vaccinated remain susceptible to infection (Bubar et al., 2021).”
Althobaity, Y. M., Wu, J., & Tildesley, M. J. (2022) · Infectious Disease Modelling · doi:10.1016/j.idm.2022.08.005 · Cited by 17
Evaluation of vaccination strategies for the metropolitan area of Madrid via agent-based simulation
Singh, D. E., Lucerón, C. O., Sánchez, A. L., Guzmán-Merino, M., Gonzalez, C. D., Delgado‐Sanz, C., Gómez‐Barroso, D., Carretero, J., & Marinescu, M.-C. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-065937 · Cited by 11
“Medium term, we will address the limitations we are reporting, starting with the implementation of pathologies and a more realistic transportation model.”
BackgroundSivadas, N., Panda, P., & Mahajan, A. (2022) · IEEE Transactions on Computational Social Systems · doi:10.1109/tcss.2022.3210404 · Cited by 11
“Only vaccination was unable to control rather a simultaneous action of vaccination, and NPIs were needed to be carried out [6], [13].”
BackgroundIntermediate levels of asymptomatic transmission can lead to the highest epidemic fatalities
Park, S. W., Dushoff, J. G., Grenfell, B. T., & Weitz, J. S. (2023) · PNAS Nexus · doi:10.1093/pnasnexus/pgad106 · Cited by 12
“Another option is to rely on the all-or-nothing assumption (59– 61); for simplicity, we do not explore this option.”
Antioch, K. M. (2023) · Journal of Public Health · doi:10.1007/s10389-023-01919-z · Cited by 11
“Modeling the best allocation of vaccines (e.g., Bubar et al. 2021) is often based on epidemiological outcomes such as deaths, years of life lost, or numbers of infections and possibly on the costs of delivering such outcomes.”
Robust Combination Testing: Methods and Application to COVID-19 Detection
Jain, S., Jónasson, J. O., Pauphilet, J., & Ramdas, K. (2023) · Management Science · doi:10.1287/mnsc.2023.4826 · Cited by 11
Shiri, M., Fattahi, P., & Sogandi, F. (2024) · Scientific Reports · doi:10.1038/s41598-024-67071-0 · Cited by 10
Carta, M., Marinello, I., Cappelletti, A., Rodolfi, A., Cerrito, E., Bernasconi, C., Gottardo, M., Lago, F. D., Rizzetto, D., Barzon, E., et al. (2021) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqab107 · Cited by 11
Metadata
- Authors
- Bubar, K. M., Reinholt, K., Kissler, S. M., Lipsitch, M., Cobey, S., Grad, Y. H., & Larremore, D. B.
- Affiliations
- University of Colorado Boulder (US)
- Harvard University (US)
- University of Chicago (US)
- Corresponding author
- Bubar, Kate M.
- Larremore, Daniel B.
- ORCID
- Venue
- Science
- Published
- 2021-02-26
- Volume
- 371
- Issue
- 6532
- Pages
- 916-921
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC7963218
- OpenAlex
- W3123021790
- Cited by
- 775
- References
- 45
- Citations by year
- 2026: 32 · 2025: 56 · 2024: 87 · 2023: 109 · 2022: 222 · 2021: 261
- FWCI
- 65.62
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Science (publishedVersion, cc-by)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Knowledge@UChicago (University of Chicago) (submittedVersion, cc-by-nc-nd)
- PubMed Central (submittedVersion, cc-by-nc-nd)
- Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion, cc-by)
- ImmPort
- University of Chicago (cc-by)
- Funders
- National Institutes of Health (3U24GM132013-02S2)
- Morris-Singer Fund
- Topics
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- COVID-19 vaccine prioritization, SARS-CoV-2, serostatus, serological testing, transmission-blocking vaccine, vaccine inequity, cumulative incidence, mortality, years of life lost, naturally acquired immunity, vaccine supply
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.